Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Whitehawk Therapeutics IncNASDAQ: WHWK

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$34.79M, compared with -$227.57M a year earlier.

Context

  • Net debt amounted to 27.3% of total assets at the end of Q1 FY2026, down 69.9 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +84.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$34.79M+7.4% QoQ
Last fiscal yearDec 2025
-$37.57M-35.0% YoY
Year agoMar 2025
-$227.57M+84.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.7%——
1 year-35.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(37.57M) USD
Year-over-year change
-35.0%

Net Debt vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +84.7% is the 3rd highest of 9, against a peer median of +55.1%.
  • Net debt amounts to 27.3% of total assets for WHWK, versus a peer median of 51.1%.
WHWK Competitors
Net Debt for WHWK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLNNClene Inc.Mar 2026$16.11M USD+45.0%+6.9%74.4%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$6.72M USD+2809.5%-5.6%2.7%
PLRXPliant Therapeutics, Inc.Mar 2026$6.59M USD+120.8%—3.3%
ONCYOncolytics Biotech Inc.Mar 2026-CA$4.99M CAD+65.1%—61.1%
MGNXMacroGenics, Inc.Mar 2026-$30.01M USD+72.2%—13.8%
WHWKWhitehawk Therapeutics IncMar 2026-$34.79M USD+84.7%—27.3%
CNTXContext Therapeutics Inc.Mar 2026-$54.25M USD+39.2%—92.2%
IMMXImmix Biopharma, Inc.Mar 2026-$78.21M USD-426.3%—81.6%
OVIDOvid Therapeutics Inc.Mar 2026-$92.61M USD-1280.9%—41.0%
Peer median (excluding WHWK) —+55.1%+0.6%51.1%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents148.99M39.02M62.89M28.67M37.57M
Short-term Investments0133.54M45.96M18.57M108.13M
Net Receivables01.86M5.49M5.9M0
Inventory01.86M6.43M5.31M0
Other Current Assets003.83M03.32M
Total Current Assets151.27M180.03M124.59M61.29M149.01M
Property, Plant & Equipment (Net)614K2.03M5.97M7.63M3K
Goodwill00000
Intangible Assets3.81M0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.21M2.18M1.87M1.4M1.81M
Total Non-current Assets6.64M4.21M7.84M9.03M1.82M
Total Assets157.91M184.24M132.42M70.32M150.83M
Account Payables6.44M3.52M5.9M2.16M917K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.47M1.57M3.08M64K3.16M
Total Current Liabilities15.27M18.84M26.4M17.07M14.52M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.76M5.76M0202K0
Total Non-current Liabilities6.23M7.02M833K767K0
Total Liabilities21.5M25.86M27.23M17.84M14.52M
Common Stock2K2K2K2K4K
Retained Earnings(142.69M)(203.2M)(268.96M)(332.65M)(353.25M)
Accumulated OCI0(115K)27K16K120K
Other Stockholders Equity00000
Minority Interest00000
Total Equity136.41M158.38M105.2M52.48M136.31M
Total Debt605K1.66M1.27M833K0
Net Debt(148.38M)(37.36M)(61.62M)(27.84M)(37.57M)

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.